# Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

> **NCT00651703** · PHASE2 · COMPLETED · sponsor: **Cytos Biotechnology AG** · enrollment: 21 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** CYT004-MelQbG10 + Montanide
- **BIOLOGICAL:** CYT004-MelQbG10 + Montanide + Imiquimod
- **BIOLOGICAL:** CYT004-MelQbG10 + Imiquimod
- **BIOLOGICAL:** CYT004-MelQbG10 intra nodal injection

## Key facts

- **NCT ID:** NCT00651703
- **Lead sponsor:** Cytos Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-12
- **Final completion:** 2010-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2010-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651703, "Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00651703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*